Skip to main content

Table 5 Microbiologic response at the isolate level: selected baseline isolates at test-of-cure visit (ME population)

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  Tigecycline Imipenem/cilastatin
Isolate N MIC90 % (95% CI) N MIC90 % (95% CI)
Bacteroides fragilis 30/43 2.0 69.8 (53.9, 82.8) 29/40 0.5 72.5 (56.1, 85.4)
Citrobacter spp. 13/15 1.0 86.7 (59.5, 98.3) 5/7 0.5 71.4 (29.0, 96.3)
Clostridium spp. 16/19 1.0 84.2 (60.4, 96.6) 14/18 2.0 77.8 (52.4, 93.6)
Enterobacter spp. 6/8 1.0 75.0 (34.9, 96.8) 5/10 1.0 50.0 (18.7, 81.3)
Enterococcus faecalis (non-VRE) 10/16 0.25 62.5 (35.4, 84.8) 9/18 4.0 50.0 (26.0, 74.0)
Escherichia coli 135/168 0.5 80.4 (73.5, 86.1) 152/182 0.25 83.5 (77.3, 88.6)
Fusobacterium spp. 3/5 0.25 60.0 (14.7, 94.7) 6/7 0.25 85.7 (42.1, 99.6)
Klebsiella spp. 27/31 1.0 87.1 (70.2, 96.4) 36/42 0.25 85.7 (71.5, 94.6)
Peptostreptococcus spp. 6/10 0.12 60.0 (26.2, 87.8) 5/8 0.25 62.5 (24.5, 91.5)
Proteus spp. 5/10 4.0 50.0 (18.7, 81.3) 3/3 4.0 100.0 (29.2, 100.0)
Pseudomonas aeruginosa 13/18 32.0 72.2 (46.5, 90.3) 19/21 2.0 90.5 (69.6, 98.8)
Staphylococcus aureus (MRSA) 1/2 NA 50.0 (1.3, 98.7) 0/1 NA 0.0 (0.0, 97.5)
S. aureus (non-MRSA) 7/8 0.25 87.5 (47.3, 99.7) 3/4 0.12 75.0 (19.4, 99.4)
Streptococcus spp. 63/81 0.12 77.8 (67.2, 86.3) 46/67 0.12 68.7 (56.2, 79.4)
  1. MRSA = methicillin-resistant Staphylococcus aureus; VRE = vancomycin-resistant enterococci.
  2. NA = MIC90 values are not valid if the number of isolates is less than 10.